Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid

Abstract

(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 can be used to treat addiction and neurological disorders without side effects such as visual field defects caused by vigabatrin (Sabril).

We claim: 
     
         1 . A method of treating a condition selected from a neurological disorder or a psychological disorder comprising administering a gamma-amino butyric acid (GABA) aminotransferase inhibitor which does not prevent the reuptake of GABA. 
     
     
         2 . The method of  claim 1  wherein the gamma-amino butyric acid transferase inhibitor inactivates GABA aminotransferase through a di-fluoromethylene intermediate instead of 4-oxohex-5-enoic acid. 
     
     
         3 . The method of  claim 2  wherein the GABA aminotransferase inhibitor is (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or its salts. 
     
     
         4 . The method of  claim 1  where in the treatment has reduced collateral damage when compared to the administration of an effective amount of vigabatrin. 
     
     
         5 . The method of  claim 4  wherein the collateral damage that is reduced is selected from visual field defects and intramyelinic edema. 
     
     
         6 . The method of  claim 3  wherein the (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or its salts is administered at a dose from 0.05 to 2.5 mg/kg/day or from about 3.5 to about 175 mg/day for an average adult. 
     
     
         7 . The method of  claim 1  wherein the patient suffers from a psychological disorder selected from one or more of the following: general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders. 
     
     
         8 . The method of  claim 1  wherein the neurological disorder is selected from epilepsy, fibromyalgia, neuropathic pain, migraine related to epilepsy, restless leg syndrome and post traumatic stress disorder addiction, obesity, obsessive-compulsive disorders and Alzheimer's disease. 
     
     
         9 . A method of treating a psychological disorder or a neurological disorder comprising: administering a gamma-amino butyric acid (GABA) aminotransferase inhibitor which inactivates GABA aminotransferase through a di-fluoromethylene intermediate instead of 4-oxohex-5-enoic acid. 
     
     
         10 . The method of  claim 9  wherein the gamma-amino butyric acid transferase gamma-amino butyric acid (GABA) aminotransferase inhibitor does not prevent the reuptake of GABA. 
     
     
         11 . The method of  claim 10  wherein the GABA aminotransferase inhibitor is (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or its salts. 
     
     
         12 . The method of  claim 9  where in the treatment has reduced collateral damage when compared to the administration of an effective amount of vigabatrin. 
     
     
         13 . The method of  claim 12  wherein the collateral damage that is reduced is selected from visual field defects and intramyelinic edema. 
     
     
         14 . The method of  claim 10  wherein the (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or its salts is administered at a dose from 0.05 to 2.5 mg/kg/day or from about 3.5 to about 175 mg/day for an average adult. 
     
     
         15 . The method of  claim 9  wherein the psychological disorder is selected from one or more of the following: general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders. 
     
     
         16 . The method of  claim 12  wherein the neurological disorder is selected from epilepsy, fibromyalgia, neuropathic pain, migraine related to epilepsy, restless leg syndrome and post traumatic stress disorder addiction, obesity, obsessive-compulsive disorders and Alzheimer's disease.